<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424915</url>
  </required_header>
  <id_info>
    <org_study_id>18-058</org_study_id>
    <nct_id>NCT03424915</nct_id>
  </id_info>
  <brief_title>Exercise, Fitness and Tumor Profiling in Breast Cancer Patients</brief_title>
  <official_title>Integrative Profiling of Primary Breast Cancer on the Basis of Divergent Exercise Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to find out how engaging in regular exercise (or not) alters the&#xD;
      biology of breast tumors as well as the normal tissue (if available) surrounding the tumor.&#xD;
      The investigators hope that findings from this initial study will guide the design of future&#xD;
      studies to examine how changes in exercise alter breast tumor biology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>differences in DNA somatic mutational profile</measure>
    <time_frame>2 years</time_frame>
    <description>Eight-μm-thick representative sections of the fresh-frozen sample will be microdissected with a needle under a stereomicroscope (Olympus SZ61), to ensure &gt;70% of tumor cell content as previously described.(36) Matched germline DNA will be microdissected from adjacent normal breast tissue (if available) for each case; to avoid the possibility of morphologically appearing non-neoplastic cells harboring somatic mutations; we will prioritize the microdissection of stromal cells and avoid normal breast ducts and lobules.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>differences in RNA sequencing</measure>
    <time_frame>2 years</time_frame>
    <description>The initial analysis will focus on immune signatures (i.e., immune activation, as well as preexisting immune and related signatures) characterization using RNA-seq</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Regular exercisers and non-exercising groups who have been diagnosed with breast cancer</arm_group_label>
    <description>There is no treatment on this study, it is a onetime assessment. exercisers: ≥120 minutes of vigorous-intensity aerobic exercise;There is no treatment on this study, it is a onetime assessment. non-exercisers: ≤ 30 minutes of moderate-intensity exercise per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular exercisers who are at high risk of developing breast cancer</arm_group_label>
    <description>≥120 minutes of vigorous-intensity aerobic exercise;</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Harvard Health Professionals survey</intervention_name>
    <description>Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.</description>
    <arm_group_label>Regular exercisers and non-exercising groups who have been diagnosed with breast cancer</arm_group_label>
    <arm_group_label>Regular exercisers who are at high risk of developing breast cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Participant will provide a blood sample</description>
    <arm_group_label>Regular exercisers and non-exercising groups who have been diagnosed with breast cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CPET Procedures</intervention_name>
    <description>CPET with 12-lead ECG</description>
    <arm_group_label>Regular exercisers and non-exercising groups who have been diagnosed with breast cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool sample</intervention_name>
    <description>Research stool sample (within ±1 week of surgery), if possible</description>
    <arm_group_label>Regular exercisers and non-exercising groups who have been diagnosed with breast cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Research Tissue sampling</intervention_name>
    <description>Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.</description>
    <arm_group_label>Regular exercisers and non-exercising groups who have been diagnosed with breast cancer</arm_group_label>
    <arm_group_label>Regular exercisers who are at high risk of developing breast cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue from the mastectomy or lumpectomy specimen may be obtained, may either acquire a fresh&#xD;
      frozen research tumor and adjacent normal tissue sample or formalin fixed paraffin embedded&#xD;
      (FFPE) tissue for molecular profiling Blood and research stool sample (if possible)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MSK clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1: Breast Cancer Patients&#xD;
&#xD;
          -  Ages 21-80 years&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Histologically confirmed ER receptor positive (&gt;1% staining), HER2 negative (FISH&#xD;
             ratio &lt;1.8), untreated operable breast cancer&#xD;
&#xD;
          -  Stage I to II disease&#xD;
&#xD;
          -  Scheduled for surgical resection by any type of mastectomy or lumpectomy at MSK&#xD;
&#xD;
          -  Tumor size ≥1cm by preoperative imaging or physical examination&#xD;
&#xD;
          -  Categorization into self-reported exercise history exposure classifications as&#xD;
             follows: (1) exercising: ≥120 minutes of vigorous-intensity exercise/wk for the past&#xD;
             12 months, and (2) sedentary (non-exercising): ≤ 30 minutes of moderate-intensity&#xD;
             exercise/week for the past months using the Harvard Health Professionals survey.(34)&#xD;
&#xD;
          -  Ability to read and understand English&#xD;
&#xD;
          -  Willing and able to comply with requirements of the protocol&#xD;
&#xD;
        Cohort 2: High-Risk Patients&#xD;
&#xD;
          -  Women at high-risk of breast cancer, as defined by one of the following:&#xD;
&#xD;
               -  Cytologically confirmed atypical hyperplasia&#xD;
&#xD;
               -  confirmed LCIS&#xD;
&#xD;
               -  Being a carrier for BRCA1 and/or BRCA2&#xD;
&#xD;
               -  Predicted lifetime risk of breast cancer &gt;20% based on family history&#xD;
&#xD;
               -  Predicted 10-year risk of breast cancer of ≥2.31%&#xD;
&#xD;
               -  Predicted 5-year risk of breast cancer ≥1.67%&#xD;
&#xD;
          -  Aged 21-80 years old&#xD;
&#xD;
          -  If a female of child-bearing potential, must not be pregnant or planning to become&#xD;
             pregnant during the study.&#xD;
&#xD;
               -  Women &lt;50 years old of child-bearing potential must have a negative pregnancy&#xD;
                  test (urine HCG or serum) within 14 days of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort 1:&#xD;
&#xD;
          -  Received any form of neoadjuvant treatment&#xD;
&#xD;
          -  Presence of any other concurrent, actively treated malignancy&#xD;
&#xD;
          -  Presence of metastatic disease&#xD;
&#xD;
          -  If performing a CPET, any of the following contraindications:&#xD;
&#xD;
               -  Acute myocardial infarction within 3-5 days of any planned study procedures;&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Uncontrolled arrhythmia causing symptoms or hemodynamic compromise&#xD;
&#xD;
               -  Recurrent syncope&#xD;
&#xD;
               -  Active endocarditis&#xD;
&#xD;
               -  Acute myocarditis or pericarditis&#xD;
&#xD;
               -  Symptomatic severe aortic stenosis&#xD;
&#xD;
               -  Uncontrolled heart failure&#xD;
&#xD;
               -  Acute pulmonary embolus or pulmonary infarction within 3 months of any planned&#xD;
                  study procedures&#xD;
&#xD;
               -  Thrombosis of lower extremities&#xD;
&#xD;
               -  Suspected dissecting aneurysm&#xD;
&#xD;
               -  Uncontrolled asthma&#xD;
&#xD;
               -  Pulmonary edema&#xD;
&#xD;
               -  Respiratory failure&#xD;
&#xD;
               -  Acute non-cardiopulmonary disorders that may affect exercise performance or be&#xD;
                  aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis).&#xD;
&#xD;
          -  Mental impairment leading to inability to cooperate&#xD;
&#xD;
          -  If performing a CPET, room air desaturation at rest ≤ 85%&#xD;
&#xD;
          -  Any other condition or intercurrent illness that, in the opinion of the investigator,&#xD;
             makes the participant a poor candidate for the study.&#xD;
&#xD;
        Cohort 2:&#xD;
&#xD;
          -  Use of any selective estrogen receptor modulator or aromatase inhibitor within 6&#xD;
             months of consent, including, but not limited to: tamoxifen, raloxifene, arzoxifene,&#xD;
             acolbifene, anastrozole, exemestane, and letrozole.&#xD;
&#xD;
          -  Enrollment on an interventional investigational study&#xD;
&#xD;
          -  Bilateral breast implants&#xD;
&#xD;
          -  History of any of the following:&#xD;
&#xD;
               -  Invasive breast cancer&#xD;
&#xD;
               -  DCIS&#xD;
&#xD;
          -  Any current invasive cancer diagnosis&#xD;
&#xD;
          -  Metastatic malignancy of any kind&#xD;
&#xD;
          -  If performing a CPET, any of the following contraindications:&#xD;
&#xD;
               -  Acute myocardial infarction within 3-5 days of any planned study procedures;&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Uncontrolled arrhythmia causing symptoms or hemodynamic compromise&#xD;
&#xD;
               -  Recurrent syncope&#xD;
&#xD;
               -  Active endocarditis&#xD;
&#xD;
               -  Acute myocarditis or pericarditis&#xD;
&#xD;
               -  Symptomatic severe aortic stenosis&#xD;
&#xD;
               -  Uncontrolled heart failure&#xD;
&#xD;
               -  Acute pulmonary embolus or pulmonary infarction within 3 months of any planned&#xD;
                  study procedures&#xD;
&#xD;
               -  Thrombosis of lower extremities&#xD;
&#xD;
               -  Suspected dissecting aneurysm&#xD;
&#xD;
               -  Uncontrolled asthma&#xD;
&#xD;
               -  Pulmonary edema&#xD;
&#xD;
               -  Respiratory failure&#xD;
&#xD;
               -  Acute non-cardiopulmonary disorders that may affect exercise performance or be&#xD;
                  aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis).&#xD;
&#xD;
          -  Mental impairment leading to inability to cooperate&#xD;
&#xD;
          -  If performing a CPET, room air desaturation at rest ≤ 85%&#xD;
&#xD;
          -  Any other condition or intercurrent illness that, in the opinion of the investigator,&#xD;
             makes the participant a poor candidate for the core biopsy or the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast Cancer</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jones, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Jones, PhD</last_name>
    <phone>646-888-8103</phone>
    <email>jonesl3@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neil yengar, MD</last_name>
    <phone>646-888-4714</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent and Follow-up)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent and Follow-up)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent and Follow-up)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent and Follow-up)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent and Follow-up)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (Consent and Follow-up)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
    <contact_backup>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-4714</phone>
    </contact_backup>
    <investigator>
      <last_name>Lee Jones, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent and Follow-up)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

